0% found this document useful (0 votes)
63 views2 pages

Euell Et Al v. Merck & Co., Inc. Et Al - Document No. 24

MEMORANDUM AND ORDER re:9 MOTION to Stay filed by Merck & Co., Inc. is GRANTED. Signed by Judge E. Richard Webber on September 26, 2005. (MCB) 4:2005cv01497 Missouri Eastern District Court

Uploaded by

Justia.com
Copyright
© Public Domain
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
63 views2 pages

Euell Et Al v. Merck & Co., Inc. Et Al - Document No. 24

MEMORANDUM AND ORDER re:9 MOTION to Stay filed by Merck & Co., Inc. is GRANTED. Signed by Judge E. Richard Webber on September 26, 2005. (MCB) 4:2005cv01497 Missouri Eastern District Court

Uploaded by

Justia.com
Copyright
© Public Domain
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

Case 4:05-cv-01497-ERW Document 24 Filed 09/26/2005 Page 1 of 2

UNITED STATES DISTRICT COURT


EASTERN DISTRICT OF MISSOURI
EASTERN DIVISION

EUELL et al., )
)
Plaintiffs, )
)
vs. ) Case No. 4:05CV01497 ERW
)
MERCK & CO. et al., )
)
Defendants. )

MEMORANDUM AND ORDER

This matter comes before the Court upon Defendant Merck’s Motion to Stay [doc. #9], filed on

September 16, 2005. Plaintiffs have not opposed the Motion, and the time for doing so has expired.

This action concerns the prescription drug VIOXX, manufactured by Defendant Merck. On September

30, 2004, Defendant Merck announced that, in a clinical study known as APPROVe,1 there was an increased

relative risk for confirmed cardiovascular events beginning after 18 months of treatment in patients taking

VIOXX compared with those taking a placebo. Defendant Merck subsequently voluntarily withdrew VIOXX

from the market. Thereafter, numerous suits were filed across the nation seeking some form of recovery for

plaintiffs who had purchased and ingested VIOXX. The Judicial Panel on Multidistrict Litigation (the “MDL”)

has entered an order establishing MDL-1657, In re VIOXX Products Liability Litigation. According to

Defendant Merck, this case is a potential “tag-along” action.

A district court has the inherent power to stay its proceedings. This power is “incidental to the power

inherent in every court to control the disposition of the causes on its docket with economy of time and effort

for itself, for counsel, and for litigants.” Landis v. North American Co., 299 U.S. 248, 254 (1936). This

power requires a court to exercise its “judgment, which must weigh competing interests and maintain an even

1
The APPROVe study was a prospective, randomized, placebo-controlled clinical trial designed to
evaluate the efficacy of VIOXX 25 mg. in preventing recurrence of colorectal polyps in patients with a
history of collerectal adenomas.

PDF created with FinePrint pdfFactory trial version www.pdffactory.com


Case 4:05-cv-01497-ERW Document 24 Filed 09/26/2005 Page 2 of 2

balance.” Id. A court need not automatically stay a case merely because a party has moved the MDL for

transfer and consolidation. See Rivers v. Walt Disney, 980 F.Supp. 1358, 1360 (C.D. Cal. 1997). In

considering a motion for stay, a court should consider both the interest of judicial economy and the potential

prejudice or hardship to the parties. Id.

In its Motion, Defendant Merck requests that the Court stay all proceedings in this action pending

resolution of its motion currently before the MDL Panel for transfer of this case, and numerous other cases

with certain overlapping factual issues and similar legal theories, to a single court for coordinated pretrial

management. In support of its Motion, Defendant Merck argues that judicial economy mandates a stay. After

considering Defendant Merck’s arguments, the Court concludes that a stay is warranted. It appears likely that

this case will be included in a future conditional transfer order. This case involves the same factual inquiries

that are present in the other hundreds of VIOXX cases, including the alleged increased health risks of taking

VIOXX and whether Merck knew of these increased risks and failed to disclose them to the medical community

and consumers. The Court finds Defendant Merck’s judicial economy argument persuasive and concludes that

judicial economy weighs in favor of granting the requested stay. The Court also considers the resulting

prejudice to the parties. The Court concludes that, although Plaintiffs might well be subjected to some delay

as a result of the issuance of a stay, that prejudice does not outweigh the efficiency concerns described herein.

Therefore, Defendant Merck’s Motion will be granted.

Accordingly,

IT IS HEREBY ORDERED that Defendant Merck’s Motion to Stay [doc. #9] is GRANTED.

Dated this 26th day of September, 2005.

E. RICHARD WEBBER
UNITED STATES DISTRICT JUDGE

PDF created with FinePrint pdfFactory trial version www.pdffactory.com

You might also like